Study: AUGMENT-102: A Phase 1, Open-label, Dose-escalation Study to Evaluate Safety, Tolerability and Preliminary Anti-Leukemic Activity of SNDX-5613 in Combination with Chemotherapy in Patients with Relapsed/Refractory Leukemias Harboring a KMT2A/MLL Gene Rearrangement or Nucleophosmin 1 Mutation (mNPM1)
Please Select Your Affiliation with CU Anschutz
Thank you for expressing your interest in a research study and for taking the time to provide your information.
By clicking 'Submit', your information will be shared with the research team. Typically a member of the research team will contact you within 1 to 2 business days.
Please understand that:
- The research team will need to determine whether you are eligible for the study. Clicking 'Submit' does not enroll you into the study, or guarantee that you qualify for the study.
- It is always your choice to participate.
Thanks again. Volunteers such as yourself are at the core of our work.
